Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KJO
|
|||
| Former ID |
DIB006241
|
|||
| Drug Name |
MUT-056399
|
|||
| Synonyms |
Fab-001; MUT-1; MUT-2; MUT-3; MUT-37307; MUT-4; FabI inhibitors (antibacterial), Mutabilis; FabI inhibitors (bacterial infection), FAB Pharma
Click to Show/Hide
|
|||
| Indication | Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09; ICD-10: B95.62] | Preclinical | [1] | |
| Company |
Mutabilis SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13F2NO3
|
|||
| Canonical SMILES |
CCC1=CC(=C(C=C1F)OC2=C(C=C(C=C2)C(=O)N)F)O
|
|||
| InChI |
1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)
|
|||
| InChIKey |
QUHARGDBJJUOEB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1269055-85-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI) | Target Info | Modulator | [2] |
| Staphylococcus Enoyl ACP reductase (Stap-coc fabI) | Target Info | Modulator | [2] | |
| KEGG Pathway | Fatty acid biosynthesis | |||
| Biotin metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021501) | |||
| REF 2 | The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.